Ultralife (ULBI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
10 Mar, 2026Executive summary
Q4 2025 revenue reached $48.5 million, up 10.6% year-over-year, with a full-year total of $191.2 million, a 16.2% increase year-over-year.
Backlog grew to $110.2 million, up 22% sequentially, diversified across markets, with over $6 million from new 2025 product launches.
Operating loss for Q4 was $10.6 million, driven by a $12.2 million non-cash intangible asset impairment and $1.2 million in one-time costs; full-year operating loss was $5.9 million.
Adjusted EBITDA for Q4 was $5.7 million (11.7% of sales), up from $3.9 million (8.9%) last year.
Completed ERP transition, closed two North American facilities, and unified back-office systems.
Financial highlights
Battery and energy product segment Q4 revenue was $45.9 million, up 15.1% year-over-year; organic growth was 9.5%.
Communications Systems segment revenue declined 35.2% to $2.6 million due to delayed government orders.
Consolidated gross profit was $12.1 million, up 13.7% year-over-year; gross margin improved to 24.9%.
Net loss for Q4 was $7.4 million or $0.45 per share, including $0.57 per share for the impairment charge.
Cash balance at year-end was $9.3 million, up from $6.9 million a year earlier.
Outlook and guidance
Entering 2026 with a strong backlog and improved operational efficiency, positioning for profitable growth and incremental cash flow.
Communications Systems expected to rebound in 2026 as new products launch and delayed programs resume.
Targeting organic growth at least 2x GDP and short-term EBITDA margin above 10%.
Baseline revenue goal for Communications Systems is $25 million, with potential for large orders.
Plans to reduce debt, support strategic capital expenditures, and invest in new product development.
Latest events from Ultralife
- Q2 revenue up 13% to $48.6M, but margins and net income declined; outlook for H2 is positive.ULBI
Q2 20253 Feb 2026 - Record segment sales, margin gains, and major debt reduction highlight Q2 2024.ULBI
Q2 20243 Feb 2026 - Q3 revenue and profit declined, but debt reduction and a $50M acquisition set up future growth.ULBI
Q3 202415 Jan 2026 - Q4 revenue was $43.9M, with Electrochem acquisition and strong backlog driving 2025 growth.ULBI
Q4 202424 Dec 2025 - Director elections, auditor ratification, and governance updates highlight the 2025 proxy.ULBI
Proxy Filing1 Dec 2025 - Vote on director elections and auditor ratification at the July 16, 2025 annual meeting.ULBI
Proxy Filing1 Dec 2025 - Q1 2025 revenue up 21% to $50.7M, but net income and margins declined on higher costs.ULBI
Q1 202526 Nov 2025 - Q3 2025 revenue up 21.5% to $43.4M, but net loss of $1.22M on lower margins and one-time costs.ULBI
Q3 202519 Nov 2025